Background: Serum prolidase levels change decisively in coronary artery disease and valvular disease. The aims of this study are to determine how the serum prolidase level will vary in patients who have undergone coronary bypass surgery due to mitral insufficiency and those without ischemic mitral regurgitation and those with ischemic mitral regurgitation. Methods: A total of 45 patients who were operated with coronary bypass surgery were selected. Group 1 patients were defined as patients who had coronary artery bypass surgery and did not have mitral insufficiency (25 patients), and Group 2 patients were defined as patients who had undergone coronary artery bypass surgery and had mitral insufficiency (20 patients). Before and after coronary artery bypass surgery, blood was taken from the patients and their prolidase levels were measured. Results: In Group 1 patients, pre- and postoperative serum prolidase levels were calculated as 1038.2 and 1289.43 U/L, respectively. In Group 2 patients, pre- and postoperative serum prolidase levels were calculated as 1084.07 and 1337.74 U/L, respectively. There is a significant difference between the serum prolidase (U/L) levels in the blood of group 1 and group 2 patients entering the operation and the blood after CPB (p<0.05). Conclusion: Serum prolidase level was found to be high in both patient groups. Pre- and postoperative serum prolidase levels were higher in patients with mitral valve insufficiency. Prolidase level is increased in coronary artery disease and mitral valve insufficiency.

Background: Interleukin 33, Fetuin A and Cytokeratin 18 are important inflammatory mediators in coronary artery diseases; however, although the plasma levels of these markers are generally used for the evaluation, their pericardial levels have not been explored. This study aims to determine the pericardial behavior of these mediators in coronary artery diseases and their regression to plasma. Methods: The gene expression and protein levels of interleukin 33, Fetuin A and Cytokeratin 18 in plasma and pericardial fluid were investigated in 40 patients undergone coronary bypass surgery. Results: According to ELISA findings, Interleukin 33 and Fetuin A protein levels have been found to be significantly increased in pericardial fluid compared to plasma, p<.05. Although cytokeratin 18 protein level was also dramatically increased in pericardial fluid, it was not statistically significant. Gene expressions of interleukin 33 and Fetuin A were found to be significantly increased in pericardial fluid compared to plasma, corroborating the protein levels. Conclusions: Interleukin 33, Fetuin A and Cytokeratin 18 levels are clinically important and biomarkers that should be followed. Fluctuations of these biomolecules suggest that pericardial fluid has a potential to be used as a source of biomarkers for coronary artery diseases, even if sampling from the pericardium is not sustainable. Increased Interleukin 33 and Fetuin A proposes apoptotic machinery activated in the heart tissues of our patients. Pericardial fluid is an important target for both diagnosis and treatment because of its proximity and relationship to the heart tissue.